Protocol Ledger

Cross-Indication Benchmarks & Timelines · Empirical Biostatistics Study

Clinical Trial Attrition and Completion Timelines Across Oncology, Neurology, Rare Disease and Cardiometabolic Programs

Across 54,890 Phase II and Phase III interventional studies indexed from clinicaltrials.gov and paired with 1,184 original NDA and BLA approvals from fda.gov (2018 to 2026), therapeutic area dictates execution velocity: Oncology spans 22,601 protocols with a 1,269-day median duration, nearly double Neurology (714 days) and Metabolic (616 days).

Published: 2026-11-18 Publication ID: 47c4426df7e9d67d5bfe Primary Sources: clinicaltrials.gov & fda.gov

Why One-Size-Fits-All Clinical Timeline Benchmarks Fail Portfolio Planners

Clinical development executives, venture capital diligence teams, and academic trial offices frequently benchmark protocol cycle times against an aggregate cross-industry median (693 days and 71.0 actual participants across all 54,890 protocols in Protocol Ledger). Yet disaggregating the 2018 to 2026 empirical cohort across ten canonical MeSH and condition-mapped therapeutic areas demonstrates more than a 2.9x spread in completed study duration and a 3.5x spread in median sample size.

Oncology and Hematology (ONC) accounts for 22,601 protocols (41.17% of global Phase II and Phase III interventional volume and 53.57% of all currently active trial load at 12,884 active protocols). Despite recruiting the smallest median cohort of any therapeutic group (43.0 actual patients, driven by biomarker-selected tumor mutations, CAR-T cell therapies, and antibody-drug conjugates), completed oncology trials require a median of 1,269 calendar days (3.47 years) to reach completion due to progression-free survival (PFS), overall survival (OS), and narrow molecular screening funnels.

Table 1. Phase II and Phase III Volume, Active Load, Enrollment Size, and Completion Timelines Across 10 Therapeutic Areas
Code Therapeutic Area Protocols Active Load Completed Stopped Median N Median Days Site Discl.
ONC Oncology and Hematology 22,601 12,884 3,040 2,734 43.0 1,269.0 89.7%
OTH Rare Genetic, Women's Health, and Other 10,777 3,944 3,957 1,190 60.0 572.0 81.6%
INF Infectious Disease and Vaccines 5,536 1,149 2,510 933 152.0 456.0 82.4%
NEU Neurology, Psychiatry, and Pain 4,809 1,909 1,763 628 84.0 714.0 86.4%
IMM Immunology, Rheumatology, and Dermatology 3,376 1,326 1,249 466 119.0 690.0 78.5%
END Endocrinology, Obesity, and Metabolic 2,382 857 1,032 219 113.0 616.0 86.3%
CVM Cardiovascular and Thrombosis 2,184 831 799 245 102.5 695.0 75.2%
RSP Respiratory and Pulmonary 1,201 435 506 146 91.0 651.0 56.6%
GAS Gastroenterology, Hepatology, and Renal 1,088 422 396 140 76.0 662.5 71.5%
OPH Ophthalmology and Sensory 936 295 438 95 106.0 426.5 81.7%

Comparing Oncology, CNS, Rare Disease, and Cardiometabolic Attrition Profiles

Look closely at the divergence between raw overall termination percentages and closed-cohort termination ratios (stopped / (completed + stopped)) in Table 2. Because 12,884 of Oncology's 22,601 studies remain active, its raw termination rate appears moderate at 12.10%. However, among the 5,774 Oncology studies that have closed since 2018, 47.35% (2,734 vs 3,040) terminated prematurely, with 746 citing slow accrual and 280 citing dose-limiting toxicity or adverse events.

Neurology, Rare Disease, and the GLP-1 / Cardiometabolic Execution Advantage

Other major therapeutic pillars exhibit markedly different operational trade-offs:

  • Neurology, Psychiatry, and Pain (NEU, 4,809 protocols): Enrolls nearly double Oncology's median sample size (84.0 subjects) over 714 median days, posting a 13.06% overall stop rate (26.27% of closed studies) and one of the highest futility shares among stopped studies (54 futility stops, reflecting high placebo-response variance in psychiatric and pain endpoints and slow neurodegeneration modification).
  • Endocrinology, Obesity, and Metabolic (END, 2,382 protocols) & Cardiovascular (CVM, 2,184 protocols): Endocrinology achieves the lowest overall termination rate in biopharma at 9.19% (17.51% of closed protocols) alongside brisk 616-day completion medians and 113.0 median enrollment, buoyed by rapid patient demand in incretin/GLP-1 obesity, MASH, and diabetes trials and objective biomarker endpoints (HbA1c, percent body-weight loss). Cardiovascular programs enroll 102.5 median subjects over 695 days with an 11.22% overall stop rate.
  • Rare Genetic, Women's Health, and Other (OTH, 10,777 protocols): Completes faster (572 median days, 60.0 median enrollment) with a 23.12% closed-cohort stop rate, though monogenic rare-disease programs remain sensitive to geographic registry reach (287 slow-accrual closures).
  • Infectious Disease and Vaccines (INF, 5,536 protocols): Posts the highest overall stop rate (16.85%) alongside the largest median enrollment (152.0 subjects) and shortest duration (456 days), capturing acute COVID-19 and seasonal viral trials whose incidence waves subsided mid-enrollment.
Table 2. Closed-Cohort Attrition Ratios, Failure-Mode Breakdown, and California Site Footprint by Therapeutic Area
Therapeutic Area Overall Stop % Closed Stop % Slow Accrual Safety Stops Futility Stops CA Protocols CA Share %
Oncology and Hematology 12.10% 47.35% 746 280 126 3,297 14.6%
Rare Genetic, Women's Health, and Other 11.04% 23.12% 287 125 63 1,737 16.1%
Infectious Disease and Vaccines 16.85% 27.10% 228 99 61 832 15.0%
Neurology, Psychiatry, and Pain 13.06% 26.27% 137 68 54 1,121 23.3%
Immunology, Rheumatology, and Dermatology 13.80% 27.17% 65 70 45 1,099 32.6%
Endocrinology, Obesity, and Metabolic 9.19% 17.51% 40 25 10 658 27.6%
Cardiovascular and Thrombosis 11.22% 23.47% 58 16 19 403 18.5%
Respiratory and Pulmonary 12.16% 22.39% 22 26 12 320 26.6%
Gastroenterology, Hepatology, and Renal 12.87% 26.12% 33 15 13 262 24.1%
Ophthalmology and Sensory 10.15% 17.82% 13 11 13 317 33.9%

California's Disproportionate Immunology, Ophthalmology, and Neuro-Oncology Footprint

Geographic concentration across Table 2 also highlights where U.S. translational capacity clusters. While California hosts 18.30% of the global Phase II/III cohort overall (10,046 protocols, representing 46.92% of all 21,410 U.S.-site studies), California's share surges to 33.9% in Ophthalmology and Sensory trials (317 of 936 studies, anchored by Byers Eye Institute at Stanford, UCSF Proctor Foundation, Doheny/UCLA Stein, and Shiley Eye Institute at UC San Diego), 32.6% in Immunology, Rheumatology, and Dermatology (1,099 of 3,376 studies), and 27.6% in Endocrinology and Obesity (658 of 2,382 studies). Selecting sites outside saturated coastal hubs requires calibrating indication-specific clinic infrastructure rather than assuming uniform geographic availability.

Methodology and Multi-Condition Classification Notes

Each protocol in the Sponsor & Site Directory is assigned deterministically to a single primary therapeutic area using hierarchical MeSH and condition-keyword rules so cohort counts sum cleanly to 54,890 without double-counting basket trials. Completed duration days measure elapsed time from registered StartDate to CompletionDate after quarantining 56 placeholder completion horizons exceeding calendar year 2040.